📰 Ventricular Dysfunction News
Ventricular Dysfunction News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ventricular Dysfunction. Real-time updates on events, politics, business and more.
September 6, 2022
Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation
August 9, 2022
Erectile Dysfunction Devices Market has increased owing to the rising prevalence of erectile dysfunction cases among men. According to the CDC 2021, getting aged does not cause erectile dysfunction
August 9, 2022
/PRNewswire/ -- DelveInsights Erectile Dysfunction Devices Market Insights and Forecast report provides the current and forecast Erectile Dysfunction Devices...
June 5, 2022
Daiichi Sankyo and AstraZeneca's ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary
April 6, 2022
DUBLIN--(BUSINESS WIRE)--The "Left Ventricular Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.This pipeline guide provides comprehensive information on the therapeutics under development for Left Ven...
December 23, 2021
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the efficacy and safety of ENHERTU (trastuzumab
December 9, 2021
DESTINY-Breast03 data presented at SABCS 2021 showed Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a similar benefit in patient subgroups, including those with stable brain metastases, compared
December 1, 2021
Additional analyses of DESTINY-Breast03 trial of ENHERTU and updated results from triple negative breast cancer cohort of TROPION-PanTumor01 trial of datopotamab deruxtecan to be highlighted Daiichi
September 29, 2021
Heart of a 41-year-old woman was transplanted to 31-year-old man, who was suffering from dilated cardiomyopathy with severe left ventricular dysfunction: Global Hospital of Mumbai said.
January 27, 2021
Daiichi Sankyo Company, Limited: ENHERTU Receives Prime Ministers Award from the Japan Techno-Economics Society Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Ministers Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with th...